Physicochemical Properties
| Molecular Formula | CK2O3 |
| Molecular Weight | 138.21 |
| Exact Mass | 137.912 |
| CAS # | 584-08-7 |
| PubChem CID | 11430 |
| Appearance |
Colorless cubic crystals; hygroscopic Granules or granular powder White, deliquescent, granular, translucent powder |
| Density | 2.43 g/mL at 25 °C |
| Boiling Point | 333.6ºC at 760 mmHg |
| Melting Point | 891 °C(lit.) |
| Flash Point | 111ºC |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 0 |
| Heavy Atom Count | 6 |
| Complexity | 18.8 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | [K+].[K+].[O-]C(=O)[O-] |
| InChi Key | BWHMMNNQKKPAPP-UHFFFAOYSA-L |
| InChi Code | InChI=1S/CH2O3.2K/c2-1(3)4;;/h(H2,2,3,4);;/q;2*+1/p-2 |
| Chemical Name | dipotassium;carbonate |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Applications for potassium carbonate in industry and research are numerous. Potassium carbonate is mostly used in the production of glass, chemicals, fertilizers, and soap. It is employed as a scavenger for acids generated during organic synthesis and as a desiccant for solvents, particularly when there are traces of acids present. It serves as a buffering agent in the wine-making process. In fire extinguishers, it is also employed as a fire extinguishing agent. It is a commonly used reagent in organic synthesis for alkylation and arylation processes involving carbon, sulfur, nitrogen, and oxygen centers. Moreover, it is employed in a number of other reactions, including hydration, metal-catalyzed cross-coupling reactions, aldol condensations, Michael reactions, acylations, Wittig reactions, Knoevenagel reactions, elimination reactions, epoxy resin ring opening, and recycling. |
| Toxicity/Toxicokinetics |
Toxicity Data LC (rat) = > 500 mg/m3 Interactions Changes in urinary parameters (electrolyte levels and pH) and DNA synthesis and the morphology of the bladder epithelium were investigated in rats that were fed for 4 to 6 weeks on diets containing various Na, K, Mg, or Ca carbonate salts (3%) with or without L-ascorbic acid (5%). Beside increases in urinary pH and electrolyte levels, DNA synthesis in the bladder epithelium was increased in groups given sodium bicarbonate /and/ potassium carbonate with or without L-ascorbic acid. Furthermore some morphological alterations in the bladder epithelium were induced. Administration of ascorbic acid in combination with the salts induced levels of change greater than those with the salts alone. After administration of ascorbic acid with NH4Cl alone ... those effects on the bladder epithelium were not observed. Therefore, the authors suggest that the degree of DNA synthesis and/or morphological alteration in the rat bladder epithelium after treatment with various bases may depend on changes in urinary concentrations of sodium or potassium ions and/or pH and the presence of ascorbic acid in the urine. Non-Human Toxicity Values LD50 Rat oral >2000 mg/kg LD50 Rat oral 1870 mg/kg LD50 Mouse oral 2570 mg/kg |
| Additional Infomation |
Potassium carbonate is a potassium salt that is the dipotassium salt of carbonic acid. It has a role as a catalyst, a fertilizer and a flame retardant. It is a carbonate salt and a potassium salt. Potassium carbonate (K2CO3) is a white salt, soluble in water (insoluble in ethanol) which forms a strongly alkaline solution. It can be made as the product of potassium hydroxide's absorbent reaction with carbon dioxide. It presents a large capacity to absorb moisture. See also: Potassium Cation (has active moiety); Carbonate Ion (has active moiety); Bryonia alba root; potassium carbonate (component of) ... View More ... Therapeutic Uses MEDICATION (VET): EXPTL IN SHEEP FEEDS TO REDUCE INCIDENCE OF URINARY CALCULI. ALKALIZER; DIURETIC AGENT MEDICATION (VET): DEGREASING AGENT, KERATIN SOFTENER For the temporary relief of symptoms due to constipation: abdominal bloating, abdominal discomfort, irregularity of bowel movements. ... Disclaimer: This homeopathic product has not been evaluated by the Food and Drug Administration for safety or efficacy. FDA is not aware of scientific evidence to support homeopathy as effective. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.2354 mL | 36.1768 mL | 72.3537 mL | |
| 5 mM | 1.4471 mL | 7.2354 mL | 14.4707 mL | |
| 10 mM | 0.7235 mL | 3.6177 mL | 7.2354 mL |